잠시만 기다려 주세요. 로딩중입니다.

편두통에서의 칼시토닌유전자관련펩티드 표적 치료: 편두통 치료의 새로운 시대

Calcitonin Gene-Related Peptide Targeting Therapies for Migraine: A New Era for Migraine Treatment

대한신경과학회지 2020년 38권 2호 p.88 ~ 99
박홍균, 김병건,
소속 상세정보
박홍균 ( Park Hong-Kyun ) - Inje University College of Medicine Ilsan Paik Hospital Department of Neurology
김병건 ( Kim Byung-Kun ) - Eulji University School of Medicine Nowon Eulji Medical Center Department of Neurology

Abstract


Development of medications targeting the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor has ushered in the new era for the treatment of migraine. Some of these drugs are approved by the USA Food and Drug Administration and European Medicines Agency since 2018, and others are in the process of approval. Since the CGRP-related therapies act directly on the migraine pathophysiology, they have advantages over conventional treatments not only in effect but also in terms of adverse effects. CGRP receptor antagonist have an effect on both acute and preventive treatment of migraine, while monoclonal antibodies for CGRP ligand (fremanezumab, galcanezumab, and eptinezumab) or receptor (erenumab) reduce migraine frequency and related disability. Galcanezumab was approved by the Ministry of Food and Drug Safety in Korea in September 2019. As of December 2019, it is available for use in adult patients with migraine. We describe the pathophysiology of CGRP in migraine, summarize the results of recent CGRP antagonism related clinical trials, and provide opinions about the use of CGRP-related therapies in clinical practice.

키워드

Calcitonin gene-related peptide; Migraine disorders; Monocloncal antibodies; Calcitonin gene-related peptide antagonists

원문 및 링크아웃 정보

등재저널 정보